Document and Entity Information - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2023

Mar. 19, 2024

Jun. 30, 2023

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Dec. 31, 2023

Document Fiscal Year Focus

2023

Document Fiscal Period Focus

FY

Trading Symbol

TSHA

Entity Registrant Name

Taysha Gene Therapies, Inc.

Entity Central Index Key

0001806310

Current Fiscal Year End Date

--12-31

Entity Current Reporting Status

Yes

Entity Filer Category

Non-accelerated Filer

Entity Small Business

true

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Entity Shell Company

false

Entity File Number

001-39536

Entity Tax Identification Number

84-3199512

Entity Address, Address Line One

3000 Pegasus Park Dr

Entity Address Address Line2

Ste 1430

Entity Address, City or Town

Dallas

Entity Address, State or Province

TX

Entity Address, Postal Zip Code

75247

City Area Code

214

Local Phone Number

612-0000

Entity Common Stock, Shares Outstanding

187,018,275

Title of 12(b) Security

Common stock, par value $0.00001 per share

Security Exchange Name

NASDAQ

Entity Incorporation, State or Country Code

DE

Entity Interactive Data Current

Yes

Document Annual Report

true

Document Transition Report

false

Entity Well-known Seasoned Issuer

No

Entity Voluntary Filers

No

ICFR Auditor Attestation Flag

false

Document Financial Statement Error Correction [Flag]

false

Entity Public Float

$ 30.4

Auditor Name

Deloitte & Touche LLP

Auditor Location

Dallas, Texas

Auditor Firm ID

34

Documents Incorporated by Reference

Portions of the registrant’s definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the year ended December 31, 2023.